Governor of New York State Kathy Hochul has announced that Garonit Pharmaceutical, a global manufacturer of antiseptic products and health care solutions, will establish a state-of-the-art, 200,000-square-foot pharmaceutical manufacturing facility in New Windsor, Orange County.  

The USD 46.1 million project will become the world’s largest chlorhexidine gluconate manufacturing operation, producing antiseptic products essential for surgical disinfection and infection prevention in hospitals worldwide.

New York State is supporting this project with USD 3.8 million, including up to USD 3.5 million through the Excelsior Jobs Program and a USD 300,000 Mid-Hudson Regional Economic Development Council capital grant.

The facility is expected to significantly boost New York’s pharmaceutical manufacturing capacity while creating 100 high-quality jobs. Construction is set to begin in Q1 2026, with operations scheduled to launch in January 2027.

“New York is leading the way in reshoring pharmaceutical manufacturing, strengthening supply chains and creating high-quality jobs — and Garonit Pharmaceutical’s decision to invest in Orange County is proof of that progress,” Governor Hochul said.

“This world-class facility will produce essential antiseptic products used in surgical and hospital settings around the globe, further positioning our state as a leader in the life sciences sector. With this investment, we are not only creating good-paying jobs but also reaffirming that New York is where innovation and opportunity meet,” she added.

Strategically located near Stewart International Airport, the facility will feature advanced production lines for liquid finished dosage forms and a state-of-the-art laboratory equipped with advanced analytical equipment for quality testing and research. It will manufacture both ANDA and NDA antiseptic products approved by the US Food and Drug Administration (FDA). The initial product portfolio will focus on antiseptics designed to maintain sterility and support cleanliness during a wide range of medical procedures.   

The site will also house a fully equipped research and development center dedicated to the development of both Active Pharmaceutical Ingredients (APIs) and finished dosage forms, with a focus on bringing innovative new drugs to the US market.

Garonit Pharmaceutical owner Rohit Garg expressed gratitude for the collaboration that made the project possible.

“As the US-based owner of an API manufacturing company, I have long aspired to produce finished pharmaceutical products here in the United States. This achievement has been made possible through the invaluable support and collaboration of dedicated teams of The State of New York, Orange County, and City leaders of New Windsor,” he said.

Co-owner Nitin Garg highlighted the innovation at the core of the project, “In designing our new manufacturing facility, we were thrilled to incorporate a dedicated technology research and development center in New Windsor, which will serve as a hub for formulating new FDA-regulated products. This milestone is strengthened by our collaboration with SUNY Orange, as we work together to develop programs that bridge operational excellence with advanced research and development.”

Garonit Pharmaceutical has begun collaborating with SUNY Orange Community College to develop specialised training programs that will prepare local residents for pharmaceutical positions.

The partnership includes FDA compliance training programs and specific associate degree programs that provide opportunities to work in pharmaceutical laboratories. Garonit will also offer positions requiring bachelor's, master's, and PhD qualifications, allowing employees to work while pursuing advanced degrees.

The project is expected to generate 100 to 150 construction jobs during the build phase, and employ 100 full-time professionals in production, quality assurance, warehousing, R and D, logistics, sales, and management. Products from the facility will be exported globally, serving markets in North America, Europe, Japan, Australia, and beyond.  

Founded in 1994 in Mumbai, India, Garonit Pharmaceutical has grown into a global operation with facilities in the US, UK, India, Hong Kong, and Japan.

The New Windsor project marks a significant milestone in the company’s US expansion and aligns with New York State’s broader strategy to grow its life sciences sector and advance domestic pharmaceutical production.